Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ASBRON vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Relief of symptoms of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema,Symptomatic relief of productive cough associated with respiratory conditions
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Theophylline is primarily metabolized by cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Guaifenesin is metabolized via oxidation and glucuronidation.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
50-60% bound to albumin and alpha-1-acid glycoprotein
55–65% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 40-60%; rectal: 50-70%; inhalation: 10-30%
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 30-59 m L/min: reduce dose by 25-50%; GFR <30 m L/min: reduce dose by 50% and monitor serum theophylline levels.
No dose adjustment required for renal impairment.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B or C: reduce dose by 75% and monitor serum theophylline levels.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Weight-based: 10-16 mg/kg/day theophylline equivalent divided every 6-8 hours; maximum 400 mg/day. Adjust based on serum levels.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Elderly patients: initial dose of 130 mg orally every 8 hours; titrate gradually; monitor serum theophylline levels due to reduced clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
Theophylline has a narrow therapeutic index; serious adverse effects including seizures and arrhythmias can occur at levels close to therapeutic range. Do not exceed recommended doses. Use caution in patients with cardiac or hepatic impairment.
No FDA black box warning exists for this drug.
Theophylline toxicity is dose-related; monitor serum levels. Caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, or cardiovascular disease. Drug interactions with quinolones, macrolides, and cimetidine can increase theophylline levels.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or guaifenesin, active peptic ulcer disease, seizure disorders (unless controlled), and severe cardiac arrhythmias.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid high-fat meals with extended-release formulations as they may alter absorption. Limit caffeine-containing foods/beverages (coffee, tea, chocolate) due to additive CNS stimulation. No significant food interactions with guaifenesin.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no known teratogenicity but may cause fetal tachycardia, jitteriness, or transient neonatal effects (e.g., irritability, vomiting) due to transplacental passage. Guaifenesin: Limited human data; animal studies not indicative of teratogenicity. Overall, Asbron is considered relatively low risk, but non-pharmacologic measures preferred in first trimester.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk with an average milk-to-plasma ratio of 0.67. Maximum milk concentration correlates with maternal serum levels. With typical maternal doses, infant serum levels may reach 2-4 mcg/m L, rarely causing irritability or poor feeding. Guaifenesin is likely minimally transferred. Asbron is considered compatible with breastfeeding; observe infant for signs of theophylline side effects (jitteriness, insomnia).
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Theophylline clearance increases by 20-30% in pregnancy due to increased hepatic metabolism and volume of distribution, particularly in second and third trimesters. Starting doses should be based on non-pregnant recommendations, but maintenance doses may need to be increased by up to 30% to achieve therapeutic levels. Monitor serum levels every 1-2 weeks and adjust dose to maintain trough 5-10 mcg/m L (lower end to minimize fetal exposure). Postpartum, clearance decreases rapidly; reduce dose and monitor levels closely to avoid toxicity.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline has a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L) due to variable metabolism. Guaifenesin is an expectorant but evidence for efficacy is limited. Avoid in patients with active peptic ulcer disease or seizure disorders. Cimetidine, fluoroquinolones, and macrolides increase theophylline levels; smoking and rifampin decrease levels.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take Asbron exactly as prescribed; do not crush or chew extended-release tablets.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of theophylline toxicity: nausea, vomiting, insomnia, tremors, fast heartbeat.,Do not stop abruptly; dosage tapering may be needed.,Stay hydrated to help guaifenesin work effectively.,Avoid alcohol as it may increase side effects like dizziness.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ASBRON vs AEROLATE SR, answered by our medical review team.
ASBRON is a Bronchodilator that works by Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ASBRON and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ASBRON is: 1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ASBRON and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ASBRON is classified as Category C. Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no . AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.